We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

In related news, the American Diabetes Association released new consensus considerations and good-practice points for use of ...

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

Paramount+ offers exclusive live streams and on-demand replays of all UEFA Champions League matches and when you sign up, you ...

Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...

The FDA continues to approve new drugs and expand indications for others at a rapid pace. Here’s a summary of what happened ...

Traders are also bracing for the Reserve Bank of Australia’s rate decision later at 2.30pm AEST. But the big question ...

The FDA is expected to decide on treatments for familial chylomicronemia syndrome, type 1 diabetes, short bowel syndrome, and Prader-Willi syndrome.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...